Cytek Biosciences designs and sells spectral flow cytometry instruments and related reagents for analyzing cells in research and clinical laboratories. Its systems, including platforms such as Aurora, aim to resolve more markers from limited samples than traditional flow cytometry. The customer base includes academic labs, biopharma R&D, and clinical research settings that profile complex cell populations.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 41.5 | — | -11.4 | — |
| Q2 2025 | 45.6 | — | -5.6 | — |
| Q3 2025 | 52.3 | — | -5.5 | — |
| Q4 2025 | 62.1 | — | -44.1 | — |
| Q1 2026 | 44.1 | 6.5% | -18.9 | — |
| Q2 2026 | 48.1 | 5.6% | -12.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Sana Biotechnology, Inc. (SANA), Helen of Troy Limited (HELE), Sabre Corporation (SABR), Lexicon Pharmaceuticals, Inc. (LXRX), Fox Factory Holding Corp. (FOXF), Horizon Quantum Holdings Ltd. (HQ)